title: In vivo antioxidative and neuroprotective effect of 4-Allyl-2-methoxyphenol against chlorpyrifos-induced neurotoxicity in rat brain.
abstract: Chlorpyrifos exposure leads to various neurological disorders adverting disturbance in molecular pathways and normal brain functions. Major complications arise when these potent nerve agents access neuronal mechanisms causing adverse effect on acetylcholinesterase and brain lipids with generation of reactive oxygen species. Chlorpyrifos elicits chronic intoxication leading to redox disturbance with irreversible brain damage and oxidative stress. In the present study, neuroprotective and anti-apoptotic effects of eugenol (EO), a phenolic antioxidant, against chlorpyrifos-induced neurotoxicity was explored on rat brain cortex. Rats treated orally with chlorpyrifos [89.4 mg/kg body weight (BW)] for 15 consecutive days showed changes in brain lipid profile, increased levels of lipid peroxidation, inhibition of acetylcholinesterase activity, and changes in antioxidant enzymes. EO (250 mg/kg BW), administered 1 h after chlorpyrifos treatment, restored lipid, acetylcholinesterase, and antioxidant enzyme levels of brain cortex by suppressing chlorpyrifos-induced oxidative stress and neurotoxicity. Histological findings further demonstrated damage to brain morphology with increased protein levels of caspase-3 in CPF-treated animals. Alterations caused by neurotoxic effects of chlorpyrifos were attenuated by EO administration with decreased protein expressions of caspase-3. Thus, through its antioxidant and anti-apoptotic activities, EO showed protective effect against chlorpyrifos-induced neuronal damage.
authors.affiliation: Department of Biochemistry, Panjab University, Chandigarh, India, varsha_sh@hotmail.com.
authors.forename: Varsha
authors.initials: V
authors.lastname: Singh
authors.forename: Rupali
authors.initials: R
authors.lastname: Panwar
mesh_terms: D000110:Acetylcholinesterase; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects / Q000473:pathology; D053148:Caspase 3 / Q000096:biosynthesis; D004390:Chlorpyrifos / Q000633:toxicity; D002784:Cholesterol / Q000032:analysis; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D005054:Eugenol / Q000494:pharmacology*; D038983:Galactolipids / Q000032:analysis; D005978:Glutathione / Q000032:analysis; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D020258:Neurotoxicity Syndromes / Q000188:drug therapy* / Q000517:prevention & control*; D010084:Oxidation-Reduction / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D010743:Phospholipids / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism
chemical_list: D000975:Antioxidants; D002800:Cholinesterase Inhibitors; D038983:Galactolipids; D018696:Neuroprotective Agents; D010743:Phospholipids; D017382:Reactive Oxygen Species; D005054:Eugenol; D002784:Cholesterol; D000110:Acetylcholinesterase; D053148:Caspase 3; D005978:Glutathione; D004390:Chlorpyrifos